Drug Profile
Cinaciguat
Alternative Names: BAY-582667Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Developer Bayer HealthCare Pharmaceuticals
- Class Antihypertensives; Carboxylic acids
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Decompensated heart failure
Most Recent Events
- 25 Nov 2013 Discontinued - Phase-II for Decompensated heart failure in Canada, Croatia, Czech Republic, France, Finland, Germany, Hungary, Ireland, Israel, Italy, Japan, Lithuania, Poland, Russia, Serbia, Slovenia, Spain, South Africa and the USA (IV)
- 12 Nov 2013 No development reported - Phase-II for Decompensated heart failure in Canada, Croatia, Czech Republic, France, Finland, Germany, Hungary, Ireland, Israel, Italy, Japan, Lithuania, Poland, Russia, Serbia, Slovenia, Spain, South Africa and the USA (IV)
- 14 Mar 2011 Bayer terminates phase II trial (COMPOSE 2) in Decompensated heart failure in Germany and Ireland (NCT01067859)